CytoSorbents completes 1-for-20 reverse stock split effective Sept 8, 2026

Cytosorbents Corp

Reverse split effective 12:01 a.m. ET Sept 8, 2026; approved by shareholders at Aug 13, 2026 annual meeting.
Pre-split shares outstanding: 63,022,020; every 20 shares reclassified to 1 share, par value unchanged.
No fractional shares; fractional entitlements rounded up to nearest whole share; Equiniti Trust is exchange agent.
Outstanding options and warrants proportionally adjusted with corresponding exercise price changes.
New CUSIP 23283X305; trading on Nasdaq continues on split-adjusted basis from Sept 8, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.